Mandate

Vinge advises Adelis Equity Partners on the establishment of Adelis Equity Partners Fund IV

March 03, 2025 Private Funds

Vinge has advised Adelis Equity Partners on the establishment of Adelis’ fourth flagship fund: Adelis Equity Partners Fund IV.

The fund, which was significantly oversubscribed, held its final closing on 28 February 2025 after having raised commitments of EUR 1.6 billion from an investor base consisting of leading pension funds, foundations and fund-of-funds across Europe and North America, and from the Adelis team. The fund raise entails a more than 50% increase in commitments relative to the predecessor fund, Adelis Equity Partners Fund III. Since its commencement in 2013, Adelis invests in well-positioned companies in the Nordic and DACH regions and has to date made 45 platform investments and more than 260 add-on acquisitions.

Vinge’s team primarily consisted of Mattias Schömer, Nils Unckel, Martin Cronsioe, Ulf Nilsson, Mikaela Reinhammar, Anton Sjökvist, Emelie Svanberg, Tobias Onegård Karlsson, Viktoria Wnuk, Rebecka Margolin, Saga Meyer Viklund and Emelie Zingmark.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026